Specialty Pharmacy

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

Genglycos wins accelerated approval to cut daily cornstarch reliance in patients aged 8 and older with the rare metabolic disorder.

Garetosmab-grts cut new heterotopic ossification lesions by 90% or more at 56 weeks in the phase 3 OPTIMA trial.

Beyond financial considerations, the emotional meaning of retirement is an often-forgotten question.

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

Pharmacists who understand both the clinical and the contractual dimensions of these policies are positioned to translate between the payer's cost logic and the provider's patient safety argument.

Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.

Biosimilars are equally safe and cut costs. Pharmacists can ease patient fears at the counter.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Nancy Lyons, vice president and chief pharmacy officer at Health Mart, explains how McKesson Amplify and pharmacist-told patient care stories are driving advocacy wins for independent pharmacies at the state and federal levels.

Niki Shah, MHSA, MBA, CCHW, discusses how Project Oasis, a new diabetic retinopathy screening pilot, and the company's Community Health Worker scholarship program are working together to reduce barriers to care in under-resourced communities

From artificial intelligence (AI)-driven dispensing to specialty service diversification, Jaime Montuoro, PharmD, previews the education lineup at McKesson ideaShare 2026.

Giants of MS is one of the field’s most prestigious honors, awarded at the 2026 Consortium for MS Centers (CMSC) 2026 Annual Meeting.

At Duke Neurological Disorders Clinic, Jenelle Hall Montgomery, PharmD, BCACP, CPP, isn’t just advising on medications—she’s prescribing them, switching them, and managing the full arc of a patient’s therapy.

Phase 3 SARC041 data show that abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

Hidden payer site-of-care restrictions delay specialty infusions, driving administrative burden and patient harm—and show why transparent criteria and better coordination matter.

Subgroup data show ofatumumab sharply cuts relapses, MRI lesions, and neurodamage markers in highly active relapsing MS vs teriflunomide.

Genetic analysis links low vitamin D and earlier menarche to higher AQP4-IgG NMOSD risk, reshaping prevention and sparking calls for diverse studies.

Phase 3 FENhance trial data show CNS-penetrant BTK inhibitor fenebrutinib cuts relapses and MRI lesions in relapsing MS.

New data show ublituximab boosts MS quality of life fast and may start in 1 infusion for relapsing multiple sclerosis.

New data show cladribine tablets deliver strong relapse control and reassuring safety in older adults with relapsing multiple sclerosis, including 65 years and older.

Frexalimab shows 3-year MRI and relapse control in relapsing multiple sclerosis with stable immunity and reassuring safety.

Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.

ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.

Hemophilia management is shifting from traditional intravenous therapies toward subcutaneous agents.

Animal pharmacy protects both farm animals and family pets through responsible medication use, compounding, and collaboration among vets, pharmacists, and owners.

Outpatient infusion and specialty pharmacy pharmacists drive safe, cost-effective oncology and chronic-care expansion, from biosimilars to community access

A strategic framework for pharmacists to successfully appeal prior authorization denials through evidence-based documentation, proper coding, and systematic follow-up to ensure patient medication access.